Diet and Lifestyle for Hair Loss on Zepbound (tirzepatide): What Actually Works

What the Zepbound Label Says About Hair Loss

In the pooled weight-management trials behind the label, hair loss was reported by 5% of patients on 5 mg, 4% on 10 mg, and 5% on 15 mg, compared with 1% on placebo [1]. The label says hair loss was associated with weight reduction and was more frequent in women: 7.1% of women versus 0.5% of men on Zepbound, and 1.3% of women versus 0% of men on placebo [1]. No Zepbound-treated patient stopped treatment because of hair loss; one placebo-treated patient did [1]. Hair loss is listed among the common adverse reactions [1].

Does Weight Loss Explain It?

The label links hair loss to weight reduction [1]. A 2026 systematic review of 24 studies found telogen effluvium and androgenetic alopecia were the predominant hair-loss subtypes reported with GLP-1 receptor agonists. Tirzepatide, associated with the greatest magnitude of weight loss in that review, was most frequently linked to telogen effluvium, and rapid weight loss was described as a potential contributor [2]. In SURMOUNT-1, mean weight change at 72 weeks was -20.9% with tirzepatide 15 mg versus -3.1% with placebo [3]. The label's hair-loss rates are similar across doses: 5%, 4% and 5% [1].

Does the Label Say Anything About Protein, Iron, Zinc, Vitamin D, Hydration, or Meal Timing?

The label does not mention protein, iron, zinc, vitamin D, biotin, hydration or meal timing in connection with hair loss. Its diet instruction is not hair-specific: Zepbound is indicated with a reduced-calorie diet and increased physical activity [1].